Volume 8, Issue 2, March 2017



Vascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia

H. Haguet, J. Douxfils, F. Mullier, C. Chatelain, C. Graux, J-M. Dogné


Update on therapy of relapsed and refractory multiple myeloma

M-C. Vekemans, K. Beel, J. Caers, N. Meuleman, G. Bries, H. Demuynck, B. De Prijck, H. De Samblanx, A. Deweweire, K. Fostier, A. Kentos, P. Mineur, M. Vaes, I. Vande Broek, A. Vande Velde, J. Van Droogenbroeck, P. Vlummens, K.L. Wu, R. Schots, M. Delforge, C. Doyen, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)


Multiple myeloma bone disease: from mechanisms to next generation therapy

R. Heusschen, J. Muller, N. Withofs, F. Baron, Y. Beguin, J. Caers


A case report of a paediatric Early T-cell Precursor Lymphoblastic Leukaemia

A-S. De Koninck, C. Dhooge, B. Denys, K. Vandepoele, N. Van Roy, M. Hofmans, J. Philippé